In a newly published investigation examining novel immune checkpoints in cervical cancer, researchers reported that elevated levels of CD112 correlate significantly with adverse clinical survival outcomes. The molecules under study, CD112, encoded by the gene NECTIN2, and CD112R, encoded by the gene PVRIG, function as emerging immune checkpoints. Prior research had shown that both checkpoints are expressed across programmed death-ligand 1 (PD-L1)-negative as well as PD-L1-positive tumor environments. Nevertheless, before the present study, the specific expression patterns and biological significance of CD112 and CD112R specifically within cervical cancer tissues had remained uncharacterized.
To characterize the clinical significance and prognostic implications of these markers, the investigators retrieved expression profiles and clinical prognosis records for cervical cancer patients from multiple databases. To confirm and extend these computational observations, the research team performed laboratory analyses utilizing clinical specimens. Specifically, the authors conducted real-time quantitative polymerase chain reaction (RT-qPCR) testing on cytology specimens and carried out immunohistochemical (IHC) staining on tissue microarrays (TMA). They subsequently evaluated the clinical utility and patient outcomes associated with CD112 and CD112R using Receiver-Operating-Characteristics (ROC) analysis alongside Kaplan-Meier Cox regression modeling.
The resulting data revealed that expression levels of both CD112 and CD112R were highly increased across almost all tumor types analyzed, including cervical cancer. The laboratory measurements from the RT-qPCR assays and the immunohistochemical evaluations of tissue microarrays were fully consistent with these broad database findings. Furthermore, the researchers observed that NECTIN2 (CD112) messenger RNA (mRNA) expression escalated progressively as cervical lesions developed, demonstrating a direct relationship between transcript levels and the progression of cervical tissue abnormalities.
The investigators also assessed the predictive utility of CD112 mRNA expression in identifying advanced pathological changes in the cervix. Using Receiver-Operating-Characteristics (ROC) analysis, the research team established that CD112 mRNA expression yielded a high area under the curve (AUC) of 0.849 for predicting lesions exceeding high-grade cervical intraepithelial neoplasia (CIN2+). Within this predictive framework, the authors identified an optimal cut-off value of 0.465 to differentiate patients who had developed more than high-grade cervical lesions.
Survival analyses confirmed that CD112 functions as an independent prognostic factor in cervical cancer patients. Elevated expression of CD112 was significantly linked to shortened overall survival (OS), demonstrating a hazard ratio (HR) of 2.97 with a 95 percent confidence interval (CI) spanning 1.05 to 8.44. In addition, CD112 over-expression was significantly associated with worse disease-free survival (DFS), presenting a hazard ratio of 3.15 and a 95 percent confidence interval of 1.15 to 8.61. For the counterpart checkpoint, over-expression of CD112R was also associated with poorer overall survival, showing a hazard ratio of 2.87 with a 95 percent confidence interval of 1.01 to 8.14; however, CD112R expression did not demonstrate a statistically significant association with disease-free survival.
Further computational evaluations revealed that the expression of CD112 and CD112R computationally inferred with immune cell infiltration patterns in cervical cancer, while showing no inferred relationship with other immune checkpoints. Based on these cumulative findings, the authors concluded that CD112 serves as a viable prognostic and immune-association biomarker in cervical cancer. Importantly, the researchers noted that while these data show the CD112/CD112R pathway warrants deeper functional and therapeutic evaluation, the findings suggest the axis merits further investigation rather than immediate designation as an established immunotherapy target.
Subject of Research: CD112 and CD112R expression and clinical prognosis in cervical cancer
Article Title: Novel immune checkpoint CD112 and CD112R can be potential prognosis biomarker in immune infiltration of cervical cancer
Article References: Chen, L., Zou, Z. K., Dong, B., Li, X., Huang, Y., Li, C., Du, M., Liu, Y., Wang, W., Tian, D., Sun, P., & Xiang, Y. (2026). Novel immune checkpoint CD112 and CD112R can be potential prognosis biomarker in immune infiltration of cervical cancer. BMC Cancer. https://doi.org/10.1186/s12885-026-17251-0
Image Credits: AI Generated
DOI: 10.1186/s12885-026-17251-0
Keywords: cervical cancer, CD112, CD112R, NECTIN2, PVRIG, immune checkpoints, PD-L1, prognostic biomarker, tissue microarray, immunohistochemical staining, RT-qPCR, cytology specimens, Receiver-Operating-Characteristics, Kaplan-Meier analysis, Cox regression, disease-free survival, overall survival, cervical intraepithelial neoplasia, immune cell infiltration
News Source: Nathaniel Bowman. (November 11, 2026). Elevated CD112 Predicts Poorer Cervical Cancer Survival in Multi-Database Analysis. Scienmag.



